MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period.
Theodora KanniM ArgyropoulouC A DinarelloJ SimardEvangelos J Giamarellos-BourboulisPublished in: Clinical and experimental dermatology (2020)